Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7194603> ?p ?o }
Showing triples 1 to 49 of
49
with 100 triples per page.
- Q7194603 subject Q7334131.
- Q7194603 subject Q8256511.
- Q7194603 subject Q8732560.
- Q7194603 subject Q8965786.
- Q7194603 subject Q8971959.
- Q7194603 subject Q9052323.
- Q7194603 abstract "Pimavanserin (ACP-103), marketed under the trade name Nuplazid, is a drug developed by Acadia Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A, with 40x selectivity over 5-HT2C, and no significant affinity or activity at 5-HT2B or dopamine receptors. Pimavanserin has met expectations for Phase III clinical trials for the treatment of Parkinson's disease psychosis, and has completed Phase II trials for adjunctive treatment of schizophrenia alongside an antipsychotic medication. It is expected to improve the effectiveness and side effect profile of antipsychotics. The results of a clinical trial examining the efficacy, tolerability and safety of adjunctive pimavanserin to risperidone and haloperidol were published in November 2012 and the results showed that pimavanserin potentiated the antipsychotic effects of subtherapeutic doses of risperidone and improve the tolerability of haloperidol treatment by reducing the incidence of extrapyramidal symptoms.On September 2, 2014, the United States Food and Drug administration granted Breakthrough Therapy status to Acadia's New Drug Application for pimavanserin.".
- Q7194603 atcPrefix "none".
- Q7194603 casNumber "706779-91-1".
- Q7194603 casSupplemental "706782-28-7 (tartrate)".
- Q7194603 fdaUniiCode "JZ963P0DIK".
- Q7194603 iupacName "N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide".
- Q7194603 pubchem "10071196".
- Q7194603 thumbnail Pimavanserin2DACS2.svg?width=300.
- Q7194603 wikiPageWikiLink Q11085.
- Q7194603 wikiPageWikiLink Q1385411.
- Q7194603 wikiPageWikiLink Q14891424.
- Q7194603 wikiPageWikiLink Q1671731.
- Q7194603 wikiPageWikiLink Q170082.
- Q7194603 wikiPageWikiLink Q18027434.
- Q7194603 wikiPageWikiLink Q18027437.
- Q7194603 wikiPageWikiLink Q208144.
- Q7194603 wikiPageWikiLink Q238516.
- Q7194603 wikiPageWikiLink Q41112.
- Q7194603 wikiPageWikiLink Q412443.
- Q7194603 wikiPageWikiLink Q415496.
- Q7194603 wikiPageWikiLink Q425046.
- Q7194603 wikiPageWikiLink Q4671580.
- Q7194603 wikiPageWikiLink Q7334131.
- Q7194603 wikiPageWikiLink Q8256511.
- Q7194603 wikiPageWikiLink Q8386.
- Q7194603 wikiPageWikiLink Q8732560.
- Q7194603 wikiPageWikiLink Q8965786.
- Q7194603 wikiPageWikiLink Q8971959.
- Q7194603 wikiPageWikiLink Q9052323.
- Q7194603 atcPrefix "none".
- Q7194603 casNumber "706779".
- Q7194603 casSupplemental "706782".
- Q7194603 iupacName "N--N--N'-carbamide".
- Q7194603 pubchem "10071196".
- Q7194603 unii "JZ963P0DIK".
- Q7194603 type ChemicalSubstance.
- Q7194603 type Drug.
- Q7194603 type ChemicalObject.
- Q7194603 type Thing.
- Q7194603 type Q8386.
- Q7194603 comment "Pimavanserin (ACP-103), marketed under the trade name Nuplazid, is a drug developed by Acadia Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A, with 40x selectivity over 5-HT2C, and no significant affinity or activity at 5-HT2B or dopamine receptors.".
- Q7194603 label "Pimavanserin".
- Q7194603 depiction Pimavanserin2DACS2.svg.